{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:14Z","timestamp":1792783214619,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Shanghai Municipal Health Commission"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11096-023-01676-9","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T13:01:31Z","timestamp":1705755691000},"page":"471-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database"],"prefix":"10.1007","volume":"46","author":[{"given":"Sha","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"5","key":"1676_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41574-020-0340-1","volume":"16","author":"M Ludgate","year":"2020","unstructured":"Ludgate M. Shining a light on thyroid eye disease. Nat Rev Endocrinol. 2020;16(5):259\u201360. https:\/\/doi.org\/10.1038\/s41574-020-0340-1.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1676_CR2","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43-g67. https:\/\/doi.org\/10.1530\/eje-21-0479.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1676_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421. https:\/\/doi.org\/10.1089\/thy.2016.0229.","journal-title":"Thyroid"},{"issue":"7","key":"1676_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","volume":"29","author":"DH Slentz","year":"2020","unstructured":"Slentz DH, Nelson CC, Smith TJ. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Expert Opin Investig Drugs. 2020;29(7):645\u20139. https:\/\/doi.org\/10.1080\/13543784.2020.1772752.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"1676_CR5","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","volume":"35","author":"S Ugradar","year":"2021","unstructured":"Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Lond). 2021;35(9):2607\u201312. https:\/\/doi.org\/10.1038\/s41433-020-01297-w.","journal-title":"Eye (Lond)"},{"issue":"6","key":"1676_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diab Endocrinol. 2021;9(6):360\u201372. https:\/\/doi.org\/10.1016\/s2213-8587(21)00056-5.","journal-title":"Lancet Diab Endocrinol"},{"issue":"7","key":"1676_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Marin\u00f2 M, Marcocci C, et al. Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest. 2022;45(7):1455\u20137. https:\/\/doi.org\/10.1007\/s40618-022-01791-w.","journal-title":"J Endocrinol Invest"},{"issue":"18","key":"1676_CR8","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"issue":"4","key":"1676_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"key":"1676_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-248335","author":"A Chow","year":"2022","unstructured":"Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep. 2022;15:e248335. https:\/\/doi.org\/10.1136\/bcr-2021-248335.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1676_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7547\/87507315-84-1-35","volume":"84","author":"DA Kessler","year":"1994","unstructured":"Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. J Am Podiatr Med Assoc. 1994;84(1):35\u20138. https:\/\/doi.org\/10.7547\/87507315-84-1-35.","journal-title":"J Am Podiatr Med Assoc"},{"issue":"2","key":"1676_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","volume":"57","author":"AM Wilson","year":"2004","unstructured":"Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57(2):127\u201334. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01968.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1676_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995522","volume":"13","author":"Q Wan","year":"2022","unstructured":"Wan Q, Li Q, Lai X, et al. Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database. Front Pharmacol. 2022;13: 995522. https:\/\/doi.org\/10.3389\/fphar.2022.995522.","journal-title":"Front Pharmacol"},{"key":"1676_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, et al. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84: 106601. https:\/\/doi.org\/10.1016\/j.intimp.2020.106601.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1676_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I, et al. OpenVigil\u2013free eyeballs on FAERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137\u20138. https:\/\/doi.org\/10.1038\/nbt.2113.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1676_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Jia Y, Sun S, et al. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol. 2020;21(1):68. https:\/\/doi.org\/10.1186\/s40360-020-00447-w.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"1676_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4526.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1676_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1676_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1676_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"issue":"4","key":"1676_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.aace.2022.01.004","volume":"8","author":"K Shah","year":"2022","unstructured":"Shah K, Charitou M. A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease. AACE Clin Case Rep. 2022;8(4):148\u20139. https:\/\/doi.org\/10.1016\/j.aace.2022.01.004.","journal-title":"AACE Clin Case Rep"},{"key":"1676_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101069","volume":"22","author":"MB Safo","year":"2021","unstructured":"Safo MB, Silkiss RZ. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am J Ophthalmol Case Rep. 2021;22: 101069. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101069.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"1676_CR23","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/iop.0000000000001943","volume":"37","author":"DC Ashraf","year":"2021","unstructured":"Ashraf DC, Jankovic I, El-Nachef N, et al. New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy. Ophthalmic Plast Reconstr Surg. 2021;37(5):e160\u20134. https:\/\/doi.org\/10.1097\/iop.0000000000001943.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"1676_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/iop.0000000000001995","volume":"38","author":"I Belinsky","year":"2022","unstructured":"Belinsky I, Creighton FX Jr, Mahoney N, et al. Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg. 2022;38(1):73\u20138. https:\/\/doi.org\/10.1097\/iop.0000000000001995.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"1676_CR25","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1038\/s41598-017-04526-7","volume":"7","author":"C Lassale","year":"2017","unstructured":"Lassale C, Batty GD, Steptoe A, et al. Insulin-like growth factor 1 in relation to future hearing impairment: findings from the english longitudinal study of ageing. Sci Rep. 2017;7(1):4212. https:\/\/doi.org\/10.1038\/s41598-017-04526-7.","journal-title":"Sci Rep"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01676-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T11:06:10Z","timestamp":1711191970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01676-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01676-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}